Clinical Trials

argenx has clinical trials ongoing across its differentiated antibody pipeline

Efgartigimod

Myasthenia Gravis (MG)

ADAPT

Phase 3 trial of IV efgartigimod for the treatment of generalized MG. Completed.
Program: Efgartigimod

Primary Immune Thrombocytopenia (ITP)

ADVANCE

Phase 3 trial of IV efgartigimod for the treatment of primary ITP
Program: Efgartigimod

ADVANCE SC

Phase 3 trial evaluating IV and SC efgartigimod for the treatment of primary ITP
Program: Efgartigimod

ADVANCE2

Confirmatory Phase 3 trial of IV efgartigimod for the treatment of primary ITP
Program: Efgartigimod

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

ADHERE

Phase 2 trial of SC Efgartigimod for the treatment of CIDP
Program: Efgartigimod

Pemphigus Vulgaris (PV)

Pemphigus Vulgaris Clinical Trial

Phase 2 trial of IV efgartigimod for the treatment of PV. Active, not recruiting.
Program: Efgartigimod

Cusatuzumab

Acute Myeloid Leukemia (AML)

CULMINATE

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy
Program: Cusatuzumab

Cusatuzumab Combination (AML)

Cusatuzumab in Combination with Background Therapy for the Treatment of Participants with Acute Myeloid Leukemia
Program: Cusatuzumab

Cusatuzumab with Japanese Participants

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants with Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome who are not Candidates for Intensive Treatment
Program: Cusatuzumab

Higher-risk Myelodysplastic Syndromes (MDS)

Cusatuzumab Combination (MDS)

A Study of Cusatuzumab in Combination with Azacitidine Compared with Azacitidine Alone in Patients with Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and who are not candidates for Hematopoietic Stem Cell Transplantation
Program: Cusatuzumab

Cusatuzumab with Japanese Participants

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants with Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome who are not Candidates for Intensive Treatment
Program: Cusatuzumab

ARGX-117

Severe Autoimmunity

ARGX-117

ARGX-117 clinical trial
Program: ARGX-117